Lazabemide hydrate
CAS: 103878-84-8
Ref. 3D-DEA87884
10mg | Discontinued | ||
25mg | Discontinued | ||
50mg | Discontinued | ||
100mg | Discontinued | ||
250mg | Discontinued |
Product Information
- 2-Pyridinecarboxamide, N-(2-aminoethyl)-5-chloro-
- 6-Chloropyridine-N-(3-hydroxypropyl)-2-carbonylamide
- Ccris 7301
- Lazabemide [USAN:INN]
- N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide
- N-(2-Aminoethyl)-5-chloropicolinamide
- N-(2-aminoethyl)-5-chloropyridine-2-carboxamide
- Ro 19-6327/000
- Unii-420Hd787N9
Lazabemide hydrate is a drug that inhibits monoamine oxidase type A and B (MAO-A and MAO-B) enzymes, which are responsible for the degradation of dopamine, serotonin, and norepinephrine. It has been shown to be effective in treating bowel disease. Lazabemide hydrate can also be used to prevent or treat depression, Parkinson's disease, and other neurological disorders. Lazabemide hydrate is approved for use in the United States under the trade name Rasagiline Mesylate.